ScholarIQanswers from OpenAlex & ORCID
Thorsten Zenz
ResearcherPublications, citations & collaboration network
Thorsten Zenz is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Thorsten Zenz have?
ScholarIQindexed works
Thorsten Zenz has 491 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Thorsten Zenz have?
ScholarIQcitation count
Thorsten Zenz has 32,981 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Thorsten Zenz?
ScholarIQh-index
Thorsten Zenz has an h-index of 76 in OpenAlex.
What is the i10-index of Thorsten Zenz?
ScholarIQi10-index
Thorsten Zenz has an i10-index of 213 in OpenAlex.
What is the ORCID of Thorsten Zenz?
ScholarIQorcid
The ORCID for Thorsten Zenz is on the source record.
What is the OpenAlex record for Thorsten Zenz?
ScholarIQopenalex
The OpenAlex for Thorsten Zenz is on the source record.
What are the most-cited papers on Thorsten Zenz?
ScholarIQmost cited works
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson, AM Fink, R. Busch, Jiřı́ Mayer, M. Hensel, Georg Hopfinger, G Hess, Ulrich von Grünhagen, Michèle Bergmann, J. Catalano, Pier Luigi Zinzani, Federico Caligaris‐Cappio, JF Seymour, A Berrébi, Ulrich Jäger, Bruno Cazin, Marek Trněný, Anne Westermann, C-M Wendtner, BF Eichhorst, Peter Staib, Andreas Bühler, Dirk Winkler, Thorsten Zenz, Sebastian Böttcher, Matthias Ritgen, Myriam Mendila, Michael Kneba, Hartmut Döhner, S. Stilgenbauer
<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger, Manfred Hensel, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael Wenger, Günter Fingerle‐Rowson, Peter Lichter, Mario Cazzola, Clemens‐Martin Wendtner, Anna Maria Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz, Alexander Kröber, Katrin Scherer, Sonja Häbe, Andreas Bühler, Axel Benner, Tina Denzel, Dirk Winkler, Jennifer Edelmann, Carsten Schwänen, Hartmut Döhner, Stephan Stilgenbauer
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Peter Dreger, Hartmut Döhner, Matthias Ritgen, Sebastian Böttcher, Raymonde Busch, Sascha Dietrich, Donald Bunjes, Sandra Cohen, Jörg Schubert, Ute Hegenbart, Dietrich W. Beelen, Matthias Zeis, Michael Stadler, Justin Hasenkamp, Lutz Uharek, Christof Scheid, Andreas Humpe, Thorsten Zenz, Dirk Winkler, Michael Hallek, Michael Kneba, Norbert Schmitz, Stephan Stilgenbauer, for the German CLL Study Group